Sandoz Group AG (SDZNY)

OTCMKTS · Delayed Price · Currency is USD

45.03

-0.64 (-1.39%)

May 12, 2025, 3:59 PM EDT

25.14% (1Y)

Market Cap	19.33B
Revenue (ttm)	10.38B
Net Income (ttm)	n/a
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	13.48
Dividend	0.53 (1.16%)
Ex-Dividend Date	Apr 22, 2025

Volume	4,495
Average Volume	33,569
Open	45.00
Previous Close	45.66
Day's Range	44.06 - 45.53
52-Week Range	34.36 - 49.81
Beta	n/a
RSI	61.76
Earnings Date	Aug 7, 2025

About Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1886

Employees 22,049

Stock Exchange OTCMKTS

Ticker Symbol SDZNY

Full Company Profile

Financial Performance

Financial Statements

News

Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript

10 days ago - Seeking Alpha

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comp...

13 days ago - GlobeNewsWire

Sandoz inks agreement with Shanghai Henlius for Bristol Yervoy biosimilar

13 days ago - Seeking Alpha

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to...

13 days ago - GlobeNewsWire

Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global...

14 days ago - Reuters

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financia...

27 days ago - GlobeNewsWire

Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug

Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ: AMGN) for extending and entrenching the dominant market position of its block...

4 weeks ago - Benzinga

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated

4 weeks ago - GlobeNewsWire

Amgen faces antitrust lawsuit from Sandoz over Enbrel patents

4 weeks ago - Seeking Alpha

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept ...

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US | SDZNY Stock News

4 weeks ago - GuruFocus

Switzerland's Sandoz files antitrust lawsuit against Amgen in US

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for entrenching the dominant market position of its blockbuster medicine, Enbrel (etan...

4 weeks ago - Reuters

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling infla...

4 weeks ago - GlobeNewsWire

Novartis After Sandoz: The Business Without Generics

5 weeks ago - Seeking Alpha

Competencia investiga a Sandoz, Alliance Healthcare España y Bluetab Solutions

La Comisión Nacional de los Mercados y la Competencia (CNMC) sigue tirando del hilo abierto en diciembre de 2023 sobre el funcionamiento ...

5 weeks ago - elEconomista.es

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and liquidity. New facility replaces initial and unutilized USD 1.25 billion RCF,...

6 weeks ago - GlobeNewsWire

Sandoz: Upgrading To A Buy On 2028 Expectations

6 weeks ago - Seeking Alpha

Sandoz signs landmark supply and manufacturing agreement

BOUCHERVILLE, Quebec, March 18, 2025 (GLOBE NEWSWIRE) -- Sandoz Canada, the leader in generic and biosimilar medicines in Canada, has signed a 10-year, long-term supply agreement with its partner Delp...

7 weeks ago - GlobeNewsWire

Thanks to $60 Million Federal Investment - DELPHARM TO MODERNIZE ITS FACILITIES AND ENSURE CONTINUED PRODUCTION OF STERILE INJECTABLE MEDICINES IN BOUCHERVILLE

BOUCHERVILLE, QC , March 18, 2025 /CNW/ - Delpharm, a world leader in pharmaceutical outsourcing, announced that it has reached an agreement with the Government of Canada to modernize its injectable m...

7 weeks ago - Benzinga